ProShare Advisors
KRYS icon

ProShare Advisors’s Krystal Biotech KRYS Stock Holding History

ProShare Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.79M Buy
5,385
+625
+13% +$216K ﹤0.01% 681
2026
Q2 		$1.77M Sell
4,760
-417
-8% -$125K ﹤0.01% 700
2026
Q1 		$1.34M Sell
5,177
-939
-15% -$250K ﹤0.01% 739
2025
Q4 		$1.51M Buy
6,116
+399
+7% +$84K ﹤0.01% 735
2025
Q3 		$1.01M Sell
5,717
-908
-14% -$136K ﹤0.01% 811
2025
Q2 		$911K Sell
6,625
-526
-7% -$77.3K ﹤0.01% 858
2025
Q1 		$1.29M Sell
7,151
-1,697
-19% -$285K ﹤0.01% 750
2024
Q4 		$1.39M Buy
8,848
+1,967
+29% +$349K ﹤0.01% 792
2024
Q3 		$1.25M Buy
6,881
+1,727
+34% +$333K ﹤0.01% 753
2024
Q2 		$946K Sell
5,154
-711
-12% -$119K ﹤0.01% 761
2024
Q1 		$1.04M Buy
5,865
+486
+9% +$67.5K ﹤0.01% 777
2023
Q4 		$667K Buy
5,379
+740
+16% +$82.1K ﹤0.01% 884
2023
Q3 		$538K Buy
4,639
+158
+4% +$19.3K ﹤0.01% 889
2023
Q2 		$526K Buy
4,481
+185
+4% +$18.9K ﹤0.01% 924
2023
Q1 		$344K Sell
4,296
-577
-12% -$45.3K ﹤0.01% 1126
2022
Q4 		$386K Buy
4,873
+362
+8% +$26.9K ﹤0.01% 1092
2022
Q3 		$315K Buy
4,511
+161
+4% +$11.6K ﹤0.01% 1124
2022
Q2 		$285K Sell
4,350
-2,028
-32% -$126K ﹤0.01% 1240
2022
Q1 		$424K Sell
6,378
-668
-9% -$41.7K ﹤0.01% 1392
2021
Q4 		$493K Buy
7,046
+5
+0.1% +$291 ﹤0.01% 1453
2021
Q3 		$368K Sell
7,041
-1,600
-19% -$94.7K ﹤0.01% 1392
2021
Q2 		$588K Buy
8,641
+1,581
+22% +$110K ﹤0.01% 1418
2021
Q1 		$544K Buy
7,060
+1,022
+17% +$74.3K ﹤0.01% 1383
2020
Q4 		$362K Buy
+6,038
New +$302K ﹤0.01% 1485

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

ProShare Advisors's KRYS Position: Q3 2026 in Review

ProShare Advisors increased its Krystal Biotech (KRYS) stake by 13% in Q3 2026, buying an estimated $216K and bringing the position to 5,385 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #681.

ProShare Advisors first reported a position in KRYS in Q4 2020 and has held it in 24 quarters since. 243 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • ProShare Advisors held 5,385 shares of Krystal Biotech worth $1.79M as of Q3 2026.
  • ProShare Advisors bought 625 Krystal Biotech shares in Q3 2026, an estimated $216K.
  • Krystal Biotech made up ﹤0.01% of ProShare Advisors's portfolio in Q3 2026, its #681 holding.
  • ProShare Advisors first reported a position in Krystal Biotech in Q4 2020 and has held it in 24 quarters since.
  • 243 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on ProShare Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.